GSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer Antibody
By Ian Walker
GSK has entered into an exclusive license agreement with Hansoh Pharmaceutical Group for its HS-20093 antibody-drug cancer treatment, with payments of up to $1.71 billion depending upon milestones being met.
The companies said Wednesday that GSK will make an initial upfront payment of $185 million to Hansoh with the rest depending upon success-based milestones for HS-20093.
Upon commercialization of HS-20093, GSK will pay tiered royalties on global net sales outside of China's mainland, Hong Kong, Macau, and Taiwan, the companies said in a joint statement.
HS-20093 is being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple phase I and II clinical trials in China.
GSK shares at 1248 GMT were up 13.60 pence, or 0.95 at 1,446.40 pence. They are currently up 0.6% over the year to date.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
December 20, 2023 08:12 ET (13:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying